NASDAQ:NAMS NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis $20.14 +0.17 (+0.85%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$20.14 0.00 (-0.02%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About NewAmsterdam Pharma Stock (NASDAQ:NAMS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NewAmsterdam Pharma alerts:Sign Up Key Stats Today's Range$19.48▼$20.6250-Day Range$18.89▼$25.6352-Week Range$17.90▼$42.21Volume1.67 million shsAverage Volume1.77 million shsMarket Capitalization$2.42 billionP/E RatioN/ADividend YieldN/APrice Target$49.82Consensus RatingModerate Buy Company Overview NewAmsterdam Pharma is a biopharmaceutical company focused on developing oral treatments for cardiometabolic diseases, particularly conditions involving elevated cholesterol and cardiovascular risk. The company’s lead investigational medicine is obicetrapib, an oral inhibitor of cholesteryl ester transfer protein (CETP) being studied to lower LDL cholesterol. NewAmsterdam has evaluated obicetrapib both on its own and in combination with ezetimibe, including in clinical studies involving people with inherited high cholesterol or established cardiovascular disease whose cholesterol remains elevated despite existing treatment. Obicetrapib is investigational, and its development program centers on potential use alongside standard cholesterol-lowering therapies. The company is headquartered in the Netherlands and is led by Chief Executive Officer Michael Davidson. Its research and clinical development work is aimed at addressing unmet needs in cholesterol management and cardiovascular health.AI Generated. May Contain Errors. Read More NewAmsterdam Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreNAMS MarketRank™: 3.42703270721 of 5 starsNewAmsterdam Pharma scored higher than 69% of companies evaluated by MarketBeat, and ranked 231st out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNewAmsterdam Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNewAmsterdam Pharma has a consensus price target of $49.82, representing about 147.4% upside from its current price of $20.14.Amount of Analyst CoverageNewAmsterdam Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NewAmsterdam Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NewAmsterdam Pharma are expected to decrease in the coming year, from ($1.48) to ($2.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NewAmsterdam Pharma is -11.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NewAmsterdam Pharma is -11.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNewAmsterdam Pharma has a P/B Ratio of 3.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.51% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 8.32.Change versus previous monthShort interest in NewAmsterdam Pharma has recently decreased by 14.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNewAmsterdam Pharma does not currently pay a dividend.Dividend GrowthNewAmsterdam Pharma does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.26 News SentimentNewAmsterdam Pharma has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for NewAmsterdam Pharma this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for NAMS on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership2.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, NewAmsterdam Pharma insiders have sold 1,958.24% more of their company's stock than they have bought. Specifically, they have bought $226,500.00 in company stock and sold $4,661,919.00 in company stock.Percentage Held by Insiders12.74% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NewAmsterdam Pharma's insider trading history. Receive NAMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAMS Stock News HeadlinesCantor Fitzgerald Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)November 12 at 9:28 AM | theglobeandmail.comWhat is HC Wainwright's Estimate for NAMS FY2026 Earnings?November 12 at 1:43 AM | americanbankingnews.comThis is likely to EXPLODEDr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks.November 14 at 1:00 AM | Weiss Ratings (Ad)NewAmsterdam Pharma (NASDAQ:NAMS) Stock Gets Price Target Trim from Needham & Company LLCNovember 8, 2026 | americanbankingnews.comRBC Capital Remains a Buy on NewAmsterdam Pharma Company (NAMS)November 6, 2026 | theglobeandmail.comBMO Capital Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)November 6, 2026 | theglobeandmail.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 6, 2026 | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Up Following Strong EarningsNovember 6, 2026 | americanbankingnews.comSee More Headlines NAMS Stock Analysis - Frequently Asked Questions How have NAMS shares performed this year? NewAmsterdam Pharma's stock was trading at $35.08 at the beginning of the year. Since then, NAMS shares have decreased by 42.6% and is now trading at $20.14. How were NewAmsterdam Pharma's earnings last quarter? NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) posted its quarterly earnings results on Wednesday, November, 4th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.33. The firm had revenue of $19.16 million for the quarter, compared to the consensus estimate of $8.82 million. NewAmsterdam Pharma had a negative trailing twelve-month return on equity of 31.39% and a negative net margin of 789.95%. Who are NewAmsterdam Pharma's major shareholders? Top institutional shareholders of NewAmsterdam Pharma include Medicxi Ventures Management Jersey Ltd (1.83%), Alps Advisors Inc. (0.13%), Kornitzer Capital Management Inc. KS (0.12%) and State Street Corp (0.11%). Insiders that own company stock include Nap BV Forgrowth, James N Topper, Michael H Davidson, Johannes Jacob Piete Kastelein, Douglas F Kling, Louise Frederika Kooij, Louis G Lange and Juliette Berangere Audet. View institutional ownership trends. How do I buy shares of NewAmsterdam Pharma? Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NewAmsterdam Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Novo Nordisk A/S (NVO), Oklo (OKLO), Uranium Energy (UEC), Viking Therapeutics (VKTX) and AST SpaceMobile (ASTS). Company Calendar Last Earnings11/04/2026Today11/14/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NAMS's financial health is in the Red zone, according to TradeSmith. NAMS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NAMS CIK1936258 Webwww.newamsterdampharma.com Phone352062971FaxN/AEmployees100Year Founded2019Price Target and Rating Average Price Target for NewAmsterdam Pharma$49.82 High Price Target$61.00 Low Price Target$37.00 Potential Upside/Downside+147.4%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$203.82 million Net Margins-789.95% Pretax Margin-785.29% Return on Equity-31.39% Return on Assets-28.32% Debt Debt-to-Equity RatioN/A Current Ratio11.76 Quick Ratio11.76 Sales & Book Value Annual Sales$22.50 million Price / Sales107.35 Cash FlowN/A Price / Cash FlowN/A Book Value$5.26 per share Price / Book3.83Miscellaneous Outstanding Shares119,930,000Free Float104,308,000Market Cap$2.42 billion OptionableOptionable Beta0.15 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:NAMS) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Company N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
